ClinicalTrials.gg
CompletedNCT03704428Updated Jan 13, 2021

Safety, Tolerability and PK of SHR1314 in axSpA

A Phase 1 interventional study of SHR-1314 in Axial Spondyloarthritis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-01-13.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Apr 2018, registered Sep 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Axial Spondyloarthritis with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Axial Spondyloarthritis · China.

Enrollment
13th of 13
45 · median 274
Started
2018
with 1 other
Phase 1
Only one
of the 16
Registered
3rd of 16
by date
Lead sponsor
1 of 16
Jiangsu HengRui Medicine Co., Ltd.

Among the 16 studies in Axial Spondyloarthritis with a site in China, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2018, is the only one in phase 1, and was the 3rd registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

6 of the 16 studies in Axial Spondyloarthritis with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Axial Spondyloarthritis with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety, Tolerability and Pharmacokinetics (PK) of SHR1314 with axial spondyloarthritis.

Read the detailed description

This was a phase I, multicenter, double-blind, randomized, placebo-controlled study. The study originally planned to enroll 5 cohorts of 8 subjects each (N=40).

03

Conditions studied

  • Axial Spondyloarthritis

Keywords

  • SHR1314
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of axial spondyloarthritis (axSpA) and fulfilling the 2009 ASAS classification criteria.
  2. Have a history of back pain ≥3 months with age at onset \<45 years.
  3. Have active axSpA defined as BASDAI ≥4 at screening and baseline.
  4. Have objective signs of inflammation by presence of elevated ESR and/or presence of elevated CRP.
  5. In the past had an inadequate response to at least 1 or 2 non-steroidal anti-inflammatory drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.
  6. If taking NSAIDS be on stable dose for at least 2 weeks prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection.
  2. Previous exposure to other biologic drug directly targeting Interleukin (IL)-17 or Interleukin (IL)-17 receptor.
  3. Total ankylosis of the spine.
  4. Have recently received biologics, tumor necrosis factor inhibitors or other immunomodulatory agents within 12 weeks.
  5. Have either a current diagnosis or a recent history of malignant disease.
  6. Are pregnant or breastfeeding.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Multiple subcutaneous injections of SHR-1314 dose 1

    Drug: SHR-1314

  • Experimental
    Cohort 2

    Multiple subcutaneous injections of SHR-1314 dose 2

    Drug: SHR-1314

  • Experimental
    Cohort 3

    Multiple subcutaneous injections of SHR-1314 dose 3

    Drug: SHR-1314

  • Experimental
    Cohort 4

    Multiple subcutaneous injections of SHR-1314 dose 4

    Drug: SHR-1314

  • Experimental
    Cohort 5

    Multiple subcutaneous injections of SHR-1314 dose 5

    Drug: SHR-1314

Interventions

  • Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. The safety and tolerability of multiple subcutaneous injections of SHR1314 in adult patients with axial spondyloarthritis 1.Incidence of Treatment-Emergent Adverse Events 2.Incidence of Injection site reaction

    Safety and tolerability of multiple subcutaneous injections of SHR1314 assessed by adverse events and serious adverse events. 1. Incidence of Treatment-Emergent Adverse Events 2. Incidence of Injection site reaction

    Time frame: Baseline to 169 days after dose administration

Secondary outcomes

  1. Maximum observed serum concentration (Cmax) of SHR-1314

    maximum concentration (Cmax)

    Time frame: Baseline to 169 days after dose administration

  2. Time to maximum observed serum concentration (tmax) of SHR-1314

    Time to maximum concentration (Tmax)

    Time frame: Baseline to 169 days after dose administration

  3. Time to elimination half-life (t1/2) of SHR-1314

    t1/2

    Time frame: Baseline to 169 days after dose administration

  4. Assessment of development of Anti-drug Antibodies (ADAs)

    Incidence of development of Anti-drug Antibodies (ADAs)

    Time frame: Baseline to 169 days after dose administration

  5. Proportion of Participants Achieving an ASAS20 Response

    ASAS20 Response

    Time frame: Week2, 4, 6, 8, 12,16

07

Study locations

1 site
  • Jianwen Chen
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jan 2020, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2018
First posted
Oct 12, 2018
StartActual
Apr 19, 2018
Primary completionActual
Jan 14, 2020
CompletionActual
Jan 14, 2020
Last update
Jan 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03704428
Responsible party
Sponsor
First posted
Oct 12, 2018
Start date
Apr 19, 2018
Primary completion
Jan 14, 2020
Completion
Jan 14, 2020
Last update
Jan 13, 2021

Study contacts

Fei Sun, MD
principal investigator · People's Liberation Army General Hospital
Xin Chang, MD
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vunakizumab

Start the discussion